hepatocellular carcinoma (HCC)
Conditions
Interventions
Sponsors
The Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed with HCC according to the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) of the National Health Commission, or pathologically diagnosed with HCC by biopsy of the liver; 2. Received HCC hepatectomy in the Second Affiliated Hospital of Kunming Medical University from January 2016 to January 2019; 3. No local therapy such as TACE, TAE, TAI or HAIC or systemic therapy such as targeted immunity were received before surgery; 4. Three-phase CT scan was performed within 2 months before surgery.
Exclusion criteria
Exclusion criteria: 1. If the arterial enhancement area of the liver lesion is too small to be measured (<=5mm); 2. If the main portal vein is completely blocked; 3. If the peak of aortic enhancement is not in arterial phase or portal vein enhancement is not in venous phase; 4. Patients with other severe liver, heart, brain, and/or kidney diseases; 5. Co-infected with HIV; 6. Patients with malignant tumors of other organs during the same period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic artery coefficient;Portal vein coefficient;Overall survival;Recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| The maximum diameter of tumor;Number of tumor nodules;Macrovascular invasion;Bile duct invasion;The levels of tumor markers; | — |
Countries
China
Contacts
Public ContactKe Yang
The Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed